Investor Propel Bio Management, LLC
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Propel Bio Management, LLC . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2024-05-17 13G ACHV / Achieve Life Sciences, Inc. 2,334,176
2024-02-22 13G/A APLT / Applied Therapeutics, Inc. 4,757,382 8,071,526
2023-11-03 13D/A EIGR / Eiger BioPharmaceuticals, Inc. 5,096,986 5,375,225
2023-10-20 13D EIGR / Eiger BioPharmaceuticals, Inc. 4,823,938 5,096,986
2023-09-28 13G/A EIGR / Eiger BioPharmaceuticals, Inc. 2,392,167 4,823,938
2023-08-15 13G EIGR / Eiger BioPharmaceuticals, Inc. 2,392,167
2023-05-02 13G APLT / Applied Therapeutics, Inc. 4,757,382